...
首页> 外文期刊>Critical care medicine >Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure
【24h】

Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure

机译:哺乳动物雷帕霉素抑制剂,西罗莫司和类固醇激素的辅助治疗可改善重症H1N1肺炎和急性呼吸衰竭患者的结局

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES:: Severe H1N1 pneumonia with acute respiratory failure results in infiltration of lungs due to the presence of hyperactive immune cells. Rapamycin and corticosteroids inhibit this immune response by blocking the activation of T and B cells. DESIGN:: Open-label prospective randomized controlled trial. SETTING:: A tertiary medical center, Chang Gung Memorial Hospital, located in Taiwan. PATIENTS:: Between 2009 and 2011, of 4,012 H1N1-infected patients, 38 patients with severe H1N1 pneumonia and acute respiratory failure were enrolled. MEASUREMENTS AND MAIN RESULTS:: Thirty-eight patients with confirmed H1N1 pneumonia and on mechanical ventilatory support were randomized to receive adjuvant treatment of corticosteroids with an mTOR inhibitor, either with sirolimus (Rapamune 2 mg/d) (sirolimus group, n = 19) for 14 days or without sirolimus (nonsirolimus group, n = 19). The clinical values measured included PaO2/FIO2, Sequential Organ Failure Assessment score, duration of ventilatory support, and mortality. The baseline demography was similar between the two groups. After treatment, the PaO 2/FIO2 values on day 3 (167.5 [95% CI, 86.7-209.2 mm Hg], n = 19 vs 106.8 [95% CI, 73.0-140.7 mm Hg], n = 19; p = 0.025] and day 7 (241.6 [95% CI, 185.2-297.9 mm Hg], n = 19 vs 147.0 [95% CI, 100.7-193.7 mm Hg], n = 17; p = 0.008) in the sirolimus group were significantly better over the nonsirolimus group. Similarly, the Sequential Organ Failure Assessment score on day 3 (4.3 [95% CI, 3.1-5.5]; p = 0.029) and day 7 (5.9 [95% CI, 4.8-6.9], n = 19 and 6.2 [95% CI, 4.7-7.8], n = 17, respectively) significantly improved in the sirolimus group. The liberation from a mechanical ventilator at 3 months was also better in the sirolimus combined with corticosteroids treatment. Similarly, the duration of ventilator use was significantly shorter in the sirolimus group (median, 7 vs 15 d; p = 0.03 by log-rank test). In the sirolimus combined with corticosteroids treatment group, a rapid clearance of virus also occurred after 7 days of treatment. CONCLUSIONS:: In patients with severe H1N1 pneumonia, early adjuvant treatment with corticosteroids and an mTOR inhibitor was associated with improvement in outcomes, such as hypoxia, multiple organ dysfunction, virus clearance, and shortened liberation of ventilator and ventilator days.
机译:目的:严重的H1N1肺炎,伴有急性呼吸衰竭,由于存在过度活跃的免疫细胞而导致肺部浸润。雷帕霉素和皮质类固醇通过阻断T细胞和B细胞的活化来抑制这种免疫反应。设计::开放标签的前瞻性随机对照试验。地点:台湾长庚纪念医院三级医疗中心。患者:2009年至2011年之间,共有4,012例H1N1感染患者中,有38例患有严重H1N1肺炎和急性呼吸衰竭的患者入选。测量和主要结果:38例确诊为H1N1肺炎并在机械通气支持下的患者被随机分配接受mTOR抑制剂,西罗莫司(Rapamune 2 mg / d)的皮质类固醇的辅助治疗(西罗莫司组,n = 19)持续14天或没有西罗莫司(非西罗莫司组,n = 19)。测量的临床值包括PaO2 / FIO2,器官功能衰竭评估评分,通气支持的持续时间和死亡率。两组之间的基线人口统计学相似。治疗后,第3天的PaO 2 / FIO2值(167.5 [95%CI,86.7-209.2 mm Hg],n = 19 vs 106.8 [95%CI,73.0-140.7 mm Hg],n = 19; p = 0.025 ]和西罗莫司组的第7天(241.6 [95%CI,185.2-297.9 mm Hg],n = 19 vs 147.0 [95%CI,100.7-193.7 mm Hg],n = 17; p = 0.008)明显好于西罗莫司组同样,在第3天(4.3 [95%CI,3.1-5.5]; p = 0.029)和第7天(5.9 [95%CI,4.8-6.9],n = 19)的器官功能衰竭评估评分和西罗莫司组的6.2 [95%CI,4.7-7.8],n = 17)显着改善;西罗莫司联合皮质类固醇治疗3个月时从机械呼吸机的解放也更好。西罗莫司组的呼吸机使用时间明显缩短(中位值:7 vs 15 d;对数秩检验,P = 0.03);在西罗莫司联合皮质类固醇治疗组中,治疗7天后病毒也迅速清除。 ::在患者中严重的H1N1肺炎,早期应用皮质类固醇和mTOR抑制剂的辅助治疗可改善预后,如缺氧,多器官功能障碍,病毒清除以及呼吸机和呼吸机自由时间的缩短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号